DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Friday, September 28, 2007

GlucoLight, Patent for Sentris-100™ Blood Glucose Monitoring Technology

September 26, 2007 - GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, announced that it has been awarded U.S. Patent No. 7,254,429 for the technology that is the core of the company’s first product, the Sentris-100™ glucose monitor... Sentris-100 is currently in clinical testing and the Company recently completed its first hypoglycemic “clamping study” that measured blood glucose fluctuations in volunteer subjects with Type 1 diabetes..... GlucoLight's Press Release -

Biodel , U.S. Patent Covering Lead Product Candidates VIAject(TM) and VIAtab(TM)

Sept 27, 2007 - Biodel Inc. (Nasdaq: BIOD) announced the receipt of a notice of issuance from the United States Patent and Trademark Office (USPTO) for the Company's patent encompassing VIAject(TM) and VIAtab(TM), Biodel's two product candidates in clinical trials...
...VIAject(TM) is a rapid-acting injectable human insulin intended for meal- time use by patients with Type 1 or Type 2 diabetes...VIAtab(TM) is a sublingual tablet formulation of insulin... Biodel's Press Release -

Thursday, September 27, 2007

Innocoll , phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers

September 26, 2007 – Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:
.....CollaRx® GENTAMICIN TOPICAL to commence a series of phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers... Innocoll 's Press Release -

Theratechnologies' Glucagon-like Peptide-1 (GLP-1) portfolio of analogues for the treatment of diabetes

September 26, 2007 - Theratechnologies (TSX:TH) announced the signing of a license agreement under which OctoPlus N.V. (Euronext: OCTO) has acquired exclusive worldwide rights to develop and commercialize Theratechnologies' Glucagon-like Peptide-1 (GLP-1) portfolio of analogues for the treatment of diabetes and other potential indications...
Theratechnologies' Press Release -
OctoPlus' Press Release -

Nastech Pharmaceutical, Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes

Sept. 26, 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's rapid-acting Insulin Nasal Spray in approximately 20 patients with type 2 diabetes... Nastech Pharmaceutical's Press Release -

Wednesday, September 26, 2007

Incyte , Proof-of-Concept Results For INCB13739, 11beta-HSD1 Inhibitor in Type 2 diabetes

Sept. 25, 2007--At the 2007 UBS Global Life Sciences Conference, Incyte Corporation (Nasdaq:INCY) will announce positive proof-of-concept clinical results from the following trials:
... an ongoing 28-day Phase IIa placebo-controlled two-step hyperinsulinemic clamp trial in Type 2 diabetes for INCB13739, its lead orally available 11beta-HSD1 inhibitor... Incyte's Press Release - UBS Global Life Sciences Conference [PDF Agenda] -

Tuesday, September 25, 2007

PuriCore's Vashe, Wound Therapy System

September 24, 2007-PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, announced new clinical results from successful case studies showing the safety and efficacy of its FDA-cleared Vashe Wound Therapy Solution in a variety of clinical applications... These and other positive clinical results were presented at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing Conference in New Orleans, LA, September 5-8, and will be presented this week at Georgetown University Hospital's Diabetic Limb Salvage Conference in Washington, DC... PuriCore's Press Release [PDF] -

CytRx, iroxanadine for the treatment of diabetic foot ulcers Clinical Trial Updates

Sept. 24, 2007--CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today provided updates to its designs for its clinical trials with its orally-administered molecular chaperone-based drug candidates arimoclomol for the treatment of patients with ALS and in stroke recovery, and iroxanadine for the treatment of diabetic foot ulcers... CytRx's Press Release -

Saturday, September 22, 2007

Biodel has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe

Sept 21, 2007- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun...The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients.. Biodel's Press Release -

Pfizer and EFSD, New Research Program Focused on Cardiovascular Risk in Patients with Diabetes

September 21, 2007 -Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes... Pfizer's Press Release -

Friday, September 21, 2007

Cytomedix, FDA Clearance For AutoloGel

Sep. 20, 2007 – Cytomedix, Inc. (AMEX: GTF) today announced that the FDA has granted marketing clearance for the AutoloGelTM System. The indications for use are as follows:
Under the supervision of a healthcare professional, the PRP gel produced by the AutoloGel™ System is suitable for exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds... Cytomedix's Press Release -